Glucagon-like peptide (GLP)-1 (9-36) amide-mediated cytoprotection is blocked by exendin
(9-39) yet does not require the known GLP-1 receptor.
Exendin (9-39) amide is an antagonist of glucagon-like peptide-1 (7-36) amide in humans.
Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma-suspectum venom: further evidence for an exendin receptor on dispersed acini from guinea pig pancreas J Biol Chem 1992;267:7402-7405.
The Gila's venom contains the compound Exendin which is being turned into a new drug to fight Type 2 diabetes.
Exendin is similar to a natural hormone called GLP1 and has the power to control the secretion of the body's own insulin.
Exendin was isolated from the 18-inch Gila Monster's poisonous saliva by scientists studying the eating habits of animals.
Exendin is similar to a natural hormone called GLP1 and can control the secretion of the body's own insulin.
4 was studied and shown to decrease postprandial blood glucose and promote lower caloric intake and weight loss in patients with type 2 diabetes, a major achievement.
The last company announcement was in late December reporting that the US Patent & Trademark Office issued a Right of Appeal Notice of the patent called "Modified Exendins
Agonists" which was issued to Amylin Pharmaceuticals, Inc.
(Byetta) is the first representative of this new class of incretin mimetics, first approved in 2005 for the treatment of type 2 diabetes.
4 -- Amylin Pharmaceuticals), Cone Snails (i.
The company has expanded its research and development pipeline within the filed of metabolic disorders by starting several new preclinical programs, including validation of exendin
and GLP-1 for diabetes and obesity, the mono-di-tert-butylphenols for dyslipidemia, and several new drug targets for obesity.